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A B S T R A C T
The objectives of the study were to investigate the effects of β-cyclodextrin (βCD) and
hydroxypropyl-β-cyclodextrin (HPβCD) on the solubility and dissolution rate of norfloxacin
prepared using three different methods, at drug to cyclodextrin weight ratios of 1:1, 1:2, 1:4
and 1:8. All the methods increased the solubility and dissolution rate of norfloxacin via in-
clusion complexation with βCD and HPβCD. Norfloxacin was converted from crystalline to
amorphous form through inclusion complexation. Solvent evaporation method was the most
effective method in terms of norfloxacin solubilisation, while inclusion complex of HPβCD
has higher solubility than βCD complex when prepared using the same procedure.
© 2016 Production and hosting by Elsevier B.V. on behalf of Shenyang Pharmaceutical
University. This is an open access article under the CC BY-NC-ND license (http://
creativecommons.org/licenses/by-nc-nd/4.0/).
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1. Introduction
Cyclodextrin (CD) inclusion complexation, which is the forma-
tion of host–guest inclusion complexes by weak intermolecular
interaction, has been shown to be a promising technique in en-
hancing solubility and bioavailability of poorly water soluble
drugs [1].The molecular structure of cyclodextrin appears to be
a truncated cone, generates a hydrophilic exterior surface and
a non-polar interior cavity.The central cavity of the cyclodextrin
molecule is lined with skeletal carbons and ethereal oxygens
of the glucose residues. It provides a lipophilic microenviron-
ment into which suitably sized drug molecules may enter and
be included [2].This technique has been shown to improve the
solubility of various drugs such as celecoxib [3], clofibrate [4],
cyclosporine A [5], melarsoprol [6], paclitaxel [7,8], rofecoxib [9].
The commonly available cyclodextrins are, α-, β- and
γ-cyclodextrins, which consist of six, seven and eight gluco-
pyranose units, respectively. β-Cyclodextrin (βCD) and their
derivatives, such as hydroxypropyl-βCD (HPβCD) and methyl-
βCD (MβCD), are the main excipients commonly used in
pharmaceutical formulations [10].
In general, chemical modification of CDs can alter their physi-
cal properties, especially their solubility [11]. The solubility of
βCD in water is relatively low (approximately 18.5 mg/mL at
25 °C), whereas its derivative HPβCD has a higher aqueous
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solubility (approx. 600 mg/mL at 25 °C). HPβCD is produced from
βCD by the addition of propylene oxide to some of the hydrogen
bond forming hydroxyl groups of βCD.This modification results
in better complexation property and solubility of HPβCD than
βCD. Fig. 1 shows the chemical structures of βCD and HPβCD.
There are different methods to prepare cyclodextrin inclu-
sion complexes. These methods encompass co-precipitation
[12], kneading, lyophilisation [13], spray drying [14], freeze drying
[15] and supercritical fluid technology [16].
Norfloxacin is a fluoroquinolone antibacterial with prop-
erties similar to those of ciprofloxacin, but generally less potent
in vitro. It is used mainly in the treatment of urinary-tract in-
fections and gonorrhoea. Norfloxacin was reported to have
poor solubility in water: 0.45 mg/mL at pH 7.5. The poor solu-
bility of Norfloxacin reduces the bioavailability to around 30
to 40% [17].
In the present study, solubility and dissolution enhance-
ment of β-cyclodextrin (βCD) and its derivative hydroxypropyl-
β-cyclodextrin (HPβCD) on norfloxacin was compared. Inclusion
complex was prepared using three different methods, namely,
physical trituration, kneading and solvent evaporation.The in-
clusion complex was characterised using scanning electron
microscopy, infrared spectrophotometry, powder X-ray
diffractometry, and differential scanning calorimetry.
2. Materials and methods
2.1. Materials
Norfloxacin was purchased from Boom Buying Pvt Ltd (Delhi,
India). β-Cyclodextrin (βCD) and hydroxypropyl β-cyclodextrin
(HPβCD) were supplied by Roquette (Lestrem, France). All other
materials were of analytical reagent grade.The materials were
used as received.
2.2. Preparation of inclusion complexes
β-Cyclodextrin (βCD) and its derivative hydroxypropyl
β-cyclodextrin (HPβCD) were used to prepare norfloxacin/
cyclodextrin inclusion complex at weight ratios of 1:1, 1:2, 1:4
and 1:8, using three different preparation methods, physical
trituration, kneading and solvent evaporation.
In the physical trituration method, norfloxacin and βCD or
HPβCDwere weighed, sieved andmixed evenly by slowly adding
norfloxacin into βCD and HPβCD in a mortar with light tritu-
ration. The mixture was continuously mixed for an hour
(magnetic stirrer, Fisher, UK) until a homogeneous mixture was
obtained.The mixtures were passed through a #65 mesh sieve
(0.211 mm) and kept in a closed container.
In the kneading method, βCD or HPβCD in a mortar was
wetted with sufficient amount of water (10% w/w) to obtain a
paste and norfloxacin was slowly added into the paste. Knead-
ing was performed manually for an hour and suitable amount
of water was added from time to time to maintain the con-
sistency of the paste.The mixture was dried overnight for 24 hr
in an oven (Carbolite, Hope Valley, UK) at 50 °C. The dried
complex was ground using mortar and pestle. After sieving
through a #65 mesh sieve, the inclusion complex was kept in
a closed container.
In the solvent evaporation method, norfloxacin was dis-
solved in 25 mL of acetone, while βCD or HPβCD was dissolved
in 50 mL of distilled water. The two solutions were mixed to-
gether and stirred for 1 hr (Magnetic stirrer, Fisher, UK).Acetone
was evaporated off by heating at 50 °C under constant stir-
ring. Water was then removed under reduced pressure using
rotary evaporator (Eyela,Tokyo, Japan).The mixture was placed
overnight for 24 hr in an oven at 50 °C (Carbolite, Hope Valley,
UK) to remove the residual solvent.The inclusion complex was
ground using mortar and pestle. After sieving through a #65
mesh sieve, the inclusion complex was kept in a closed
container.
2.3. Phase solubility study
Phase solubility study was performed according to the
method of Higuchi and Connors [18]. An excess amount of
norfloxacin (1 g) was added to 50 mL of distilled water con-
taining various concentrations of βCD or HPβCD (2–20 mM).The
flasks were shaken continuously at 30 °C for 3 days to reach
A B
Fig. 1 – Chemical structures of (A) βCD and (B) HPβCD.
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equilibrium. Samples of 3 mL were withdrawn and filtered
through a 0.45 μm nylon membrane filter. Filtrate (100 μL) was
diluted appropriately and assayed at 278 nm (U-2000 Spectro-
photometer, Hitachi,Tokyo, Japan). Each measurement was run
in triplicate.
The stability constant ( Kst ) was calculated from the phase
solubility diagrams using the following equation.
Kst
Slope
S slope
=
−( )0 1
The slope was obtained from the plot of norfloxacin con-
centration against βCD or HPβCD concentration. S0 was the
equilibrium solubility of norfloxacin in water.
2.4. Solubility studies
Solubility study was performed by adding an excess amount
of solid dispersions in 50 mL of distilled water.The flasks were
vortex-mixed for 3 min and agitated at 120 rounds per minute
in a water bath maintained at 30 °C for 72 hours. Samples of
3 mL were withdrawn and filtered through a 0.45 μm nylon
membrane filter. Filtrate (100 μL) was diluted appropriately and
measured spectrophotometrically (Hitachi U-2000 Spectropho-
tometer, Hitachi Ltd,Tokyo, Japan) at 278 nm. Eachmeasurement
was repeated three times.
2.5. In vitro dissolution studies
In vitro dissolution studies were performed under sink condi-
tions for both norfloxacin and the solid dispersions using USP
dissolution tester (PTWS 3CE, Pharmatest, Germany) appara-
tus II paddle method (USP XXXII, 2009).The dissolutionmedium
comprised 900 mL of distilled water maintained at 37.0 ± 0.5 °C
with paddle rotation speed of 100 rpm.The amount of powder
equivalent to 20 mg of drug was accurately weighed into each
vessel. Samples of 3 mL were withdrawn automatically at preset
time intervals of 10, 20, 30, 40, 50 and 60 minutes and filtered
through a 0.45 μL nylon membrane filter. The drug concentra-
tion in the sample was analysed using UV spectrophotometer
(Hitachi U-2000 Spectrophotometer; Hitachi Ltd, Tokyo Japan)
at 278 nm.
Dissolution efficiency was measured using the trapezoi-
dal method and was expressed as a percentage of the area of
the rectangle divided by the area of 100% dissolution in the
same time. Percent dissolution efficiency (DE) was calculated
using the following equation where y is the percentage of dis-
solved norfloxacin. DE is the area under the dissolution curve
between time points t1 and t2 expressed as a percentage of the
curve at maximum dissolution, y100, over the same period. It
was computed to compare the performance of various carri-
ers in solid dispersion formulations [19].
DE
yXdt
y X t t
Xt
t
% %( ) =
−( )
∫ 12
100 2 1
100
The time taken by samples to release 50% of drug was taken
as dissolution half life (T50%).
2.6. Determination of drug contents of inclusion
complexes
Drug content of norfloxacin in solid dispersion was deter-
mined. The solid dispersion (20 mg) was placed in 50 mL
volumetric flask. Twenty millilitres of 0.05M of sodium hy-
droxide (NaOH) solution was added and sonicated for 10
minutes. The solution was cooled down to room temperature
and volume topped up with 0.05M of NaOH solution. The so-
lution was diluted appropriately with 0.05M of NaOH and
measured at 278 nm (U2000 Spectrophotometer, Hitachi,Tokyo,
Japan). Each measurement was performed in triplicate and the
average calculated through the construction of standard cali-
bration curve.
2.7. Scanning electron microscopy
The surface morphology of samples was examined using a LEO
1530 Field Emission Scanning Electron Microscope (FESEM;
Leosupra 50VP, Carl Zeiss, Oberkochen, Germany) at 2 keV.The
samples were sputtered with a thin layer of gold to improve
the electrical conductivity prior to imaging.
2.8. Fourier transform infrared spectroscopy
Infrared spectra were recorded on FTIR (Nexus FTIR, J Thermo
Nicolet, and USA). A total of 1 mg of samples and 100 mg of
KBr were weighed and compressed into a disk. The disk was
scanned over a spectral region from 400 to 4000 cm−1 and the
spectral data were collected.
2.9. Differential scanning calorimetry
The differential scanning calorimetry measurement was per-
formed using a DSC Perkin Elmer Pyris 6 System (USA). A
sample of 3–10 mg was weighed in aluminium pans and
crimped. The samples were heated over a temperature range
of 0 °C–350 °C at a constant rate of 10 °C/min under nitrogen
flow of 20 mL/min. An empty aluminium pan was used as a
reference.
2.10. Powder X-Ray diffractometry
The physical state of norfloxacin in solid dispersions was evalu-
ated by X-ray diffractometer (Siemens D 5000, Germany) using
CuKα radiation with graphite monochromater, at a voltage of
40 kV and a current of 30 mA. The scanning rate was 6°/min
over a 2Ɵ range of 5°–80° and a chart speed of 5°/min at an
increment of 0.05°.
2.11. Statistical analysis
The results were presented in mean ± standard deviation (SD).
The solubility, T50% and DE data were analysed using one-way
analysis of variance (ANOVA). When there was a statistically
significant difference, post-hoc Tukey-HSD test was per-
formed. A statistically significant difference was considered at
P < 0.05.
538 a s i an j o u rna l o f p h a rma c eu t i c a l s c i e n c e s 1 1 ( 2 0 1 6 ) 5 3 6 – 5 4 6
3. Results and discussion
3.1. Phase solubility study
Phase solubility study was performed to investigate the solu-
bility of norfloxacin in βCD and HPβCD. From Fig. 2, it can be
seen that solubility of norfloxacin increased proportionally with
an increase in the concentration of βCD and HPβCD. Norfloxacin
in HPβCD solution demonstrated a comparatively higher solu-
bility than βCD at similar concentration, which could be
explained by a relatively higher solubilisation of norfloxacin
in HPβCD.
The stability constant (Ks) value was found to increase from
103.49 M−1 for βCD to 642.74 M−1 for HPβCD. These values in-
dicated the formation of a comparatively more stable inclusion
complex of norfloxacin/HPβCD than norfloxacin/βCD. It was re-
ported that stability constant (Ks) value between 50 and 5000 M−1
was considered as most suitable for the improvement of solu-
bility and stability of poorly soluble drugs [19].
3.2. Solubility studies
The solubility values of norfloxacin, norfloxacin/βCD and
norfloxacin/HPβCD inclusion complexes are presented in
Table 1. Norfloxacin solubility was significantly increased
(P < 0.05) with the addition of βCD amd HPβCD, irrespective of
the preparation method used. Each of the three preparation
methods could increase the solubility of norfloxacin but to a
different extent. Solvent evaporation method produced the
highest solubility of norfloxacin in βCD and HPβCD, followed
by kneading and lastly physical trituration (P < 0.05).Within the
same preparation method, it was found that norfloxacin solu-
bility was comparatively higher in HPβCD than in βCD.
For each preparation method, the concentration of both βCD
and HPβCD used to solubilise norfloxacin was critical. It was
found that further increase in βCD or HPβCD did not increase
further the solubilisation of norfloxacin.
For physical trituration method, post-hoc Tukey-HSD test
showed a statistically significant difference in solubility between
norfloxacin/βCD and norfloxacin/HPβCD. Norfloxacin/βCD and
norfloxacin/HPβCD were categorised to two different subsets.
Both norfloxacin/βCD and norfloxacin/HPβCD at ratio of 1:1 im-
proved norfloxacin solubility. Further increase in cyclodextrin
concentration from 1:1 to 1:2 did not increase further
norfloxacin solubility.
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Fig. 2 – Phase-solubility diagram of norfloxacin in aqueous solution of βCD (♦) and HPβCD (■). Mean ± SD, N = 3.
Table 1 – Solubility data of norfloxacin and norfloxacin/
βCD and norfloxacin/HPβCD. Mean ± SD, N = 3.
Code Norfloxacin:
Cyclodextrin (Ratio)
Solubility
(mg/mL)
BCD0(Norfloxacin) Norfloxacin:
No cyclodextrin (1.0:0.0)
0.39 ± 0.01
BCD1:1 (PT) Norfloxacin: βCD (1.0:1.0) 1.53 ± 0.01
BCD1:2 (PT) Norfloxacin: βCD (1.0:2.0) 1.56 ± 0.02
BCD1:3 (PT) Norfloxacin: βCD (1.0:4.0) 1.56 ± 0.02
BCD1:4 (PT) Norfloxacin: βCD (1.0:8.0) 1.53 ± 0.03
HPBCD1:1 (PT) Norfloxacin: HPβCD (1.0:1.0) 2.32 ± 0.03
HPBCD1:2 (PT) Norfloxacin: HPβCD (1.0:2.0) 2.31 ± 0.01
HPBCD1:4 (PT) Norfloxacin: HPβCD (1.0:4.0) 2.31 ± 0.01
HPBCD1:8 (PT) Norfloxacin: HPβCD (1.0:8.0) 2.38 ± 0.02
BCD1:1 (KM) Norfloxacin: βCD (1.0:1.0) 3.07 ± 0.04
BCD1:2 (KM) Norfloxacin: βCD (1.0:2.0) 3.26 ± 0.03
BCD1:4 (KM) Norfloxacin: βCD (1.0:4.0) 3.27 ± 0.03
BCD1:8 (KM) Norfloxacin: βCD (1.0:8.0) 3.26 ± 0.03
HPBCD1:1 (KM) Norfloxacin: HPβCD (1.0:1.0) 4.64 ± 0.02
HPBCD1:2 (KM) Norfloxacin: HPβCD (1.0:2.0) 4.92 ± 0.09
HPBCD1:3 (KM) Norfloxacin: HPβCD (1.0:4.0) 5.03 ± 0.03
HPBCD1:4 (KM) Norfloxacin: HPβCD (1.0:8.0) 5.05 ± 0.05
BCD1:1 (SE) Norfloxacin: βCD (1.0:1.0) 4.23 ± 0.02
BCD1:2 (SE) Norfloxacin: βCD (1.0:2.0) 5.35 ± 0.04
BCD1:4 (SE) Norfloxacin: βCD (1.0:4.0) 5.37 ± 0.04
BCD1:8 (SE) Norfloxacin: βCD (1.0:8.0) 5.28 ± 0.04
HPBCD1:1 (SE) Norfloxacin: HPβCD (1.0:1.0) 8.51 ± 0.18
HPBCD1:2 (SE) Norfloxacin: HPβCD (1.0:2.0) 10.90 ± 0.39
HPBCD1:4 (SE) Norfloxacin: HPβCD (1.0:4.0) 10.53 ± 0.46
HPBCD1:8 (SE) Norfloxacin: HPβCD (1.0:8.0) 10.63 ± 0.15
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For kneading method, the solubility of norfloxacin/βCD at
ratio of 1:1 was 3.07 mg/mL, which was approximately twofolds
of that prepared with physical trituration method (1.53 mg/mL)
at the similar ratio. The same trend applied to norfloxacin/
HPβCD. Hence, kneading method was more effective than
physical trituration in solubility enhancement.
Solvent evaporation was the best among the three prepa-
ration methods, producing the highest norfloxacin solubility
at similar ratios for both βCD and HPβCD. Norfloxacin solu-
bility was significantly increased (P < 0.05) from 0.39 mg/mL to
4.23 mg/mL (norfloxacin/βCD at ratio 1:1) and 5.35 mg/mL
(norfloxacin/βCD at ratio 1.0:2.0). However, no statistically
significant increase was observed in norfloxacin solubilit
y with further increase in βCD amount from 1.0:2.0 to 1:4
(P > 0.05). This result suggested that the ratio of norfloxacin/
βCD at 1.0:2.0 was optimum. A similar pattern was observed
with norfloxacin/HPβCD.
3.3. In vitro dissolution studies
The mean dissolution profiles of norfloxacin and norfloxacin
inclusion complexes produced using the three different prepa-
ration methods are presented in Fig. 3a and b.The dissolution
of norfloxacin was below 65%, while the dissolution of
norfloxacin/βCD and norfloxacin/HPβCD was more than 80%,
at one hour. The results showed that formation of inclusion
complex improved norfloxacin dissolution.
The results of dissolution parameters DE60 and the T50% are
presented in Table 2.The dissolution rate was statistically sig-
nificant for T50% and DE60 values (P < 0.05) when norfloxacin
and the inclusion complexes were compared. Post-hoc Tukey-
HSD test showed that norfloxacin and the inclusion complexes
could be categorised into 9 subsets for T50% and 11 subsets for
DE60. The difference in T50% or DE60 between norfloxacin/
βCD and norfloxacin/HPβCD produced using different
preparation methods was not obvious. This could be attrib-
uted to the rapid drug release within a short time.The Pearson
correlation coefficient showed that T50% values were nega-
tively associated with the solubility of norfloxacin and its
inclusion complexes (correlation coefficient = −0.467, at 0.019
level of significance).
3.4. Determination of drug content in inclusion
complexes
The content of norfloxacin was more than 97% for all inclu-
sion complexes, showing that the drug was distributed
uniformly. Furthermore, the powder was found to be free
flowing. Norfloxacin was noted to be stable under the tested
alkaline condition for 24 hours (unpublished data).
3.5. Scanning electron microscopy
Fig. 4 shows the scanning electron photomicrographs of
norfloxacin, βCD, HPβCD, norfloxacin/β-CD and norfloxacin/
HPβCD inclusion complexes prepared using the three methods.
βCD appears to be thick solid with non-smooth surface. HPβCD
appears to be porous, spherical with cavities. Norfloxacin
appears to be a compact solid with rather smooth surface.
The scanning electron photomicrographs of norfloxacin/
βCD and norfloxacin/HPβCD produced from physical trituration
method showed similar surface morphology of mixtures of
norfloxacin and βCD (Fig. 4D) and norfloxacin and HPβCD
(Fig. 4E). No complexation occurred between norfloxacin and
cyclodextrins using physical trituration method, indicating that
inclusion complex could not be produced using physical tritu-
ration method.
For kneading method, there was formation of norfloxacin/
βCD complex with rough surface and irregular shape. On the
other hand, norfloxacin was observed to be included inside
HPβCD cavity with changes of HPβCD from spherical to flat platy
shape.
As for solvent evaporation method, the porous and spheri-
cal morphology of HPβCD disappeared as a result of complex
formation with norfloxacin. Norfloxacin/HPβCD appeared as
loose aggregates of heterogeneously distributed particles with
irregular shape and rough surface.
3.6. Fourier transfrom infrared spectroscopy
Fig. 5a and b show the FTIR spectra of norfloxacin, cyclodextrins
and norfloxacin inclusion complexes. For spectrum of βCD,
maximum absorption was registered at 3320 cm−1, which cor-
responded to the vibrations of the O—H bonds in the primary
hydroxyl groups (C—6—OH) connected by the intermolecular
hydrogen bonds or in the secondary hydroxyl groups con-
nected by the intramolecular hydrogen bonds (the C—2—OH
group of one glucopyranose unit and C—3—OH group of the
adjacent glucopyranose unit) [20]. Moreover, another absorp-
tion band at 2920 cm−1 was observed which corresponded to
Table 2 – The dissolution parameters of norfloxacin,
norfloxacin/βCD and norfloxacin/HPβCD inclusion
complexes produced from different preparation
methods. Mean ± SD, N = 6.
Code DE60 (%) T50% (min)
BCD0(Norfloxacin) 45.43 ± 1.05 28.67 ± 1.75
BCD1:1 (PT) 73.03 ± 1.15 10.92 ± 1.43
BCD1:2 (PT) 75.03 ± 1.69 10.17 ± 0.68
BCD1:3 (PT) 73.42 ± 0.84 9.92 ± 0.58
BCD1:4 (PT) 76.84 ± 1.06 9.83 ± 0.68
HPBCD1:1 (PT) 75.44 ± 1.20 8.25 ± 1.04
HPBCD1:2 (PT) 75.50 ± 1.07 8.33 ± 0.82
HPBCD1:4 (PT) 83.09 ± 1.17 8.00 ± 0.45
HPBCD1:8 (PT) 82.88 ± 1.08 7.25 ± 0.76
BCD1:1 (KM) 77.95 ± 1.14 6.42 ± 0.49
BCD1:2 (KM) 78.67 ± 1.37 7.92 ± 0.86
BCD1:4 (KM) 79.57 ± 0.59 7.00 ± 0.45
BCD1:8 (KM) 81.29 ± 1.21 6.00 ± 0.45
HPBCD1:1 (KM) 80.35 ± 1.54 7.08 ± 0.38
HPBCD1:2 (KM) 76.77 ± 1.86 7.08 ± 0.38
HPBCD1:3 (KM) 76.83 ± 1.63 7.42 ± 0.66
HPBCD1:4 (KM) 75.97 ± 2.30 8.33 ± 1.29
BCD1:1 (SE) 81.35 ± 1.80 8.25 ± 0.42
BCD1:2 (SE) 81.89 ± 1.12 7.92 ± 0.38
BCD1:4 (SE) 81.93 ± 1.84 7.83 ± 0.41
BCD1:8 (SE) 83.47 ± 1.38 7.50 ± 0.45
HPBCD1:1 (SE) 83.39 ± 0.71 6.08 ± 0.58
HPBCD1:2 (SE) 84.76 ± 0.90 5.58 ± 0.20
HPBCD1:4 (SE) 81.29 ± 2.62 6.33 ± 0.41
HPBCD1:8 (SE) 77.91 ± 0.77 6.58 ± 0.74
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the stretching vibrations of the C—H bonds in the CH and CH2
groups.A broad absorption band in the region of 1400–1200 cm−1
corresponded to the vibrations of the C—H bonds in the primary
and secondary hydroxyl groups of βCD. Absorption band at
the region of 1200–1000 cm−1 represented the C—O bonds in
the ether and hydroxyl groups of βCD. The absorption bands
in the region 950–700 cm−1 corresponded to the deformation
vibrations of the C—H bonds and the pulsation vibrations in
glucopyranose cycle.
The IR spectra of HPβCD showed characteristics bands at
3400 cm−1 related to the O—H stretching vibration. C—H vi-
bration stretching was at the absorption band of 1160 cm−1,
while 1080 cm−1 absorption band corresponded to the C—O
stretching vibration.
Fig. 3 – (a) Mean dissolution profiles of norfloxacin and norfloxacin/βCD inclusion complexes produced using different
preparation method. Mean ± SD, N = 6. (b) Mean dissolution profiles of norfloxacin and norfloxacin/HPβCD inclusion
complexes produced using different preparation method. Mean ± SD, N = 6.
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Physical mixtures of norfloxacin/βCD or HPβCD showed
bands identical to norfloxacin. Absorption bands at 3600 cm−1
and 1350 cm−1 were related to NH2+ and C—O stretching
vibrations.
However, the peak at 1730 cm−1 corresponded to C=O group
disappeared in inclusion complexes prepared using knead-
ing and solvent evaporation methods, indicating chemical
interaction between norfloxacin and the apolar cavity of βCD
or HPβCD. These results suggested that carboxylic functional
group was involved in the inclusion complexation. Similar
results were obtained for other drug/complex prepared by
freeze-drying [21]. Inclusion complex prepared by solvent evapo-
ration method revealed an absorption at 1660 cm−1, which
presumably masked possible shifts of the C=O group stretch-
ing. This might be due to the formation of intramolecular
hydrogen bonds between norfloxacin and HPβCD as also docu-
mented by Baboota et al. [22].
3.7. Differential scanning calorimetry
Fig. 6 shows the thermograms of βCD, HPβCD, norfloxacin,
norfloxacin/βCD, norfloxacin/HPβCD complexes produced using
three different preparation methods. βCD and HPβCD showed
an endothermic peak around 80–100 °C which was due to the
loss of water molecule at this region of temperature. The de-
composition temperature of βCD was 320 °C and that of HPβCD
was more than 350 °C. In addition, HPβCD revealed a peak of
glass transition temperature (Tg) at 213 °C. However, the peak
was too small to be observed in the thermogram.
Norfloxacin/βCD and norfloxacin/HPβCD complexes pre-
pared using physical trituration revealed an endothermic peak
at 220 °C corresponded to the melting temperature of
norfloxacin.This indicated that physical trituration was not able
to incorporate norfloxacin inside the apolar cavity of βCD or
HPβCD.
On the other hand, kneading method produced a compara-
tively smaller endothermic peak of norflaxacin at 220 °C than
physical trituration method, for norfloxacin/βCD and
norfloxacin/ HPβCD.
BCD1:2 (SE) and HPBCD1:2 (SE) revealed a very negligible en-
dothermic peak at characteristic melting point of crystalline
norfloxacin. Solvent evaporation method was found to be more
effective in preparing an inclusion complex than the other two
methods.
Norfloxacin has an enthalpy value of 148.33 J/g. Formation
of inclusion complex is associated with reduction of en-
thalpy value. Inclusion complexes prepared using physical
triturationmethod with βCD and HPβCD at a ratio of 1:2 showed
enthalpy values of 45.11 and 12.84 J/g, respectively. The en-
thalpy values for βCD and HPβCD were reduced to 28.78 and
−1.23 J/g with kneading method and further reduced to 5.68 and
−12.00 J/g with solvent evaporation method. Preparation of in-
clusion complex using solvent evaporation method showed a
highest reduction value in enthalpy contributing to the highest
solubility values observed in both βCD and HPβCD.
3.8. Powder X-ray diffractometry
Fig. 7 shows the powder X-ray diffraction patterns of norfloxacin
and inclusion complexes prepared using three different
methods. βCD appeared to be in crystalline form while HPβCD
was in amorphous form. XRD of inclusion complexes pre-
pared using physical trituration revealed crystalline peaks of
Fig. 4 – Scanning electron photomicrographs of (A) βCD; (B) HPβCD; (C) Norfloxacin; (D) Norfloxacin/βCD (1.0:2.0), physical
trituration method; (E) Norfloxacin/HPβCD (1.0:2.0), physical trituration method; (F) Norfloxacin/βCD (1.0:2.0), kneading
method; (G) Norfloxacin/HPβCD (1.0:2.0), kneading method; (H) Norfloxacin/βCD (1.0:2.0), solvent evaporation method;
(I) Norfloxacin/HPβCD (1.0:2.0), solvent evaporation method. 1000× magnification.
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Fig. 5 – (a) FTIR spectra of (A) Norfloxacin; (B) βCD; (C) Norfloxacin/βCD inclusion complex (1:2), physical trituration method;
(D) Norfloxacin/βCD inclusion complex (1:2), kneading method and (E) Norfloxacin/βCD inclusion complex, solvent
evaporation method (1:2). (b) FTIR spectra of (A) Norfloxacin; (B) HPβCD; (C) Norfloxacin/HPβCD inclusion complex (1:2),
physical trituration method; (D) Norfloxacin/HPβCD inclusion complex (1:2), kneading method and (E) Norfloxacin/HPβCD
inclusion complex, solvent evaporation method (1:2).
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norfloxacin. Physical trituration method could not yield inclu-
sion complex with norfloxacin.
For kneading method, βCD1:2(KM) showed a significant re-
duction in the number of crystalline peaks while HPβCD1:2(KM)
revealed an amorphous appearance with negligible crystal-
line peaks. This indicated that HPβCD was able to change the
crystalline form of norfloxacin using kneading method and its
efficiency in forming inclusion complex was higher than βCD.
βCD1:2(SE) showed an amorphous appearance with negli-
gible norfloxacin peak while HPβCD1:2(SE) produced an
inclusion complex with fully amorphous form. Solvent evapo-
ration method has proven to be the best method among the
three methods used in the present study to produce an inclu-
sion complex with amorphous appearance. Amorphous form
tends to have higher solubility than crystalline form due to its
low free Gibb’s energy.
The release of enthalpy-rich water from the cyclodextrin
cavity is the main driving force for complex formation [23].The
water molecules inserted inside the cavity of cyclodextrin
cannot fit properly due to their hydrogen bonding potentials
and therefore are of higher enthalpy. In order to stabilise the
system, the energy of the system must be lowered by replac-
ing these enthalpy-rich water molecules with norfloxacin which
is less polar than water.
XRD results indicated the change of crystallinity of
norfloxacin to amorphous state. Amorphous solids have a
higher molecular mobility and energy than the crystalline form.
These properties render the amorphous systems with higher
apparent solubility and dissolution rate. HPβCD has higher solu-
bility value than βCD which could effectively solubilise more
norfloxacin in water, resulting in a higher solubility value of
norfloxacin.
3.9. Comparison of different preparation methods
When the three preparation methods, physical trituration,
kneading and solvent evaporation were compared, physical
trituration was the simplest and easiest to prepare method.
Through simple physical trituration method, βCD and HPβCD
could increase the solubility and dissolution of norfloxacin.
There was an increase of about 3.9 times with βCD and 5.9 times
with HPβCD in the solubility of norfloxacin. Physical tritura-
tion method could not reduce the crystallinity of norfloxacin
as shown in Fig. 7.
In kneading method, a wet paste was formed when water
was added to cyclodextrin. The consistency of the paste in-
creased after the addition of norfloxacin.The amount of water
used in the paste determined the ease of the kneading process.
A dry, hard mass was obtained after drying and milling was
required to obtain a fine powdered form of the complex.When
the kneading and physical trituration method was com-
pared, it was found that norfloxacin solubilisation was higher
with kneading method than physical trituration.There was an
increase of about 8.2 times with βCD and 12.6 times with HPβCD
in the solubility of norfloxacin. There was a further reduction
in the crystallinity of norfloxacin with βCD. Norfloxacin peak
disappeared, indicating the inclusion of norfloxacin in the cavity
of HPβCD. No organic solvent was involved in the kneading
method.
The solvent evaporation method involved the use of two
solvents, one organic solvent, acetone to dissolve norfloxacin
and water to dissolve βCD and HPβCD. Both solutions were mis-
cible when mixed together. A fine powdered form of the
complex was obtained after drying. There was an increase of
about 13.6 times with βCD and 27.9 times with HPβCD in the
solubility of norfloxacin. Norfloxacin was included in the cavity
of βCD and HPβCD.
4. Conclusion
The three preparation methods, physical trituration, knead-
ing and solvent evaporation, could increase the solubility and
dissolution rate of norfloxacin via formation of inclusion
complex with βCD and HPβCD. Inclusion complex of HPβCD
produced a comparatively higher solubility than that of βCD
using the same preparation procedure. Solvent evaporation
method was the most effective method in terms of norfloxacin
solubilisation. Norfloxacin was converted from crystalline to
amorphous form through inclusion complexation.
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